2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 461

Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 543

Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 183

Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 402

Alteration of the Intestinal Microbiome in the Preclinical Phase of Experimental Arthritis and the Efficacy of Microbiota Modulation in Established Arthritis in Mice

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 798

Altered Phenotype of Platelets and Neutrophils Toward Neutrophil-Platelet Interaction in Circulation of Small and Large Vessel Vasuculitis

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 214

Ambulatory and Hospital Care for Arthritis and Related Conditions in Ontario, Canada

ARHP Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 720

Ambulatory Blood Pressure and Skin Sodium Concentrations in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 696

An ANA Screening Assay Containing Multiple Antigens Increases the Sensitivity and Specificity of ANA Testing By Indirect Immunofluorescence

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 184

An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 409

An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 745

An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 398

An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 645

An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 250

An Ultrasonographic Study for Investigating Relationships with the Signs of Uric Deposition and Bone Erosion in Patients with Hyperuricemia

Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 298

Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans

Innate Immunity and Rheumatic Disease Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].